TY - JOUR T1 - Prediction of coronary disease incidence in the general population by circulating RNY(YRNA)-derived small RNA JF - medRxiv DO - 10.1101/2020.03.24.20042812 SP - 2020.03.24.20042812 AU - Vera L. Costa AU - Jean-Bernard Ruidavet AU - Vanina Bongard AU - Bertrand Perret AU - Emanuela Repetto AU - Maria G. Stathopoulou AU - Fabrizio Serra AU - Mohamed Benahmed AU - Mauduit Claire AU - Valerie Grandjean AU - Jean Ferrières AU - Laurent O. Martinez AU - Michele Trabucchi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/26/2020.03.24.20042812.abstract N2 - During the development of atherosclerotic lesion, s-RNYs (small RNAs of about 24/34 nucleotides) are derived by the processing of long Ro-associated non-coding RNAs (RNYs) in macrophages. The levels of serum s-RNYs have been found significantly upregulated in patients with coronary heart disease (CHD) compared to age-matched healthy individuals. The present study aimed to examine the predictive value of serum s-RNYs for CHD events in the general population.Within the frame of nested-case-control study, the GENES study, we measured the absolute expression of a RNY-derived small RNA, the s-RNY1-5p, in the serum of healthy individuals who encountered a CHD event within 12 years of follow-up (n = 31) (Cases) and compared them to individuals who remained event-free (Controls) (n = 30).The expression of s-RNY1-5p in serum was significantly upregulated in Cases compared to Controls (p = 0.027). The proportion of CHD event-free was significantly higher among individuals with serum s-RNY1-5p below the median value (631 molecule / mL). In a multivariate model adjusted for age, smoking and treatment for hypertension, diabetes and dyslipidemia, the risk of CHD events increased more than 4-fold in individuals with serum s-RNY1-5p above the median value (HR, 4.36; 95%CI, 1.22-15.60). Significant association with CHD events was also observed when considering s-RNY1-5p as a continuous variable (p = 0.022). Serum s-RNY1-5p is an independent predictor of CHD in healthy individuals and could be considered as a biomarker in primary prevention of cardiovascular diseases.TRANSLATIONAL PERSPECTIVES Here, we reported that s-RNY1-5p was significantly upregulated in the serum of individuals who underwent CHD and was positively associated with CHD events. Those results argue in favor of s-RNY1-5p being a novel predictive molecular biomarker for cardiovascular events. In the future, measurement of s-RNY1-5p expression levels and other 5’ s-RNYs, such as s-RNY4-5p, could be used in clinical practice in addition to classical risk factors to identify those high-risk individuals who might benefit from prevention medicine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementV.M-C. was supported by the Satt-SudEst. This work was supported by the ANR through the “Investments for the Future” # ANR-11-LABX-0028-01 (LABEX SIGNALIFE), FRM (grant #DEQ20140329551), Agence de la Biomédecine (AMP, Diagnostic prénatal et diagnostic génétique), Satt-SudEst and the Société Française de Nutrition (Prix de Recherche 2017).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall raw data in the manuscript are present in this submission ER -